If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
110
results.
Updated on
16/09/2026 [07:48:00]
Results 100 to 110 of 110
Absstract of: WO2026154387A1
Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) contains IgA antibodies against SARS-CoV-2 S glycoproteins. The method includes contacting a biological sample with a SARS-CoV-2 S glycoprotein-coated surface, contacting the surface with a secondary antibody, and detecting the secondary antibody, where if a secondary antibody is detected, the sample contains IgA antibodies against the SARS-CoV-2 S glycoprotein. Assay substrates and kits for performing such methods are also disclosed.
Absstract of: US20260209318A1
SARS-CoV-2 spike protein-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the SARS-CoV-2 spike protein-binding molecules.
Absstract of: US20260209750A1
Disclosed is a CRISPR/Cas based system for screening an RNA aptamer against a target protein, comprising: (i) a guide RNA comprising a recognition sequence and a nucleic acid aptamer random library having a predetermined length; (ii) a target sequence complementary to the recognition sequence of the guide RNA; (iii) a selection marker located downstream of the target sequence and comprising a basal promoter and a selection marker gene; (iv) a fusion protein comprising the target protein and a transcriptional activation module, wherein a binding of the target protein to an RNA aptamer of the nucleic acid aptamer random library results in recruitment of the transcriptional activation module to the selection marker; (v) a dCas protein specifically recognizing the target sequence under the guidance of the guide RNA; and (vi) a screening cell. Also disclosed is a method for screening an RNA aptamer against a target protein using the system provided herein and RNA aptamers against S1 protein of SARS-CoV-2 virus and applications thereof.
Absstract of: US20260207693A1
0000 An application of Shenling Baizhu in the preparation of a medicine for treating neuropsychiatric symptoms of recovered COVID-19 patients.
Absstract of: US20260207714A1
0000 Safe, effective, disease-modifying treatments—and especially, optimized treatments—for Alzheimer's and many other CNS, cardiovascular, metabolic and other disorders remain elusive. This is in part due to many CNS, cardiovascular, metabolic. and other disorders having underlying components on both sides of the blood-brain barrier—e.g., having CNS components as well as cardiovascular and/or metabolic and/or other non-CNS components. Respective examples in CNS, cardiovascular, metabolic and other domains include Alzheimer's disease, heart failure, diabetes and COVID-19. This is in and of itself a challenge, as most drugs (~98% of small molecules; a greater portion of larger molecules such as antibodies and peptides) do not cross the blood brain barrier appreciably, and even when they do, the chances of them having a partition coefficient that optimizes dosing in compartments on both sides of the blood brain barrier is vanishingly low. This invention addresses that challenge with a novel, bicameral, CNS+ (i.e., two-compartment, where one compartment is on the neuronal/glial side of the blood-brain barrier and one compartment is not) approach. This bicameral, CNS+ approach involves parallel 1) Intranasal, direct-to-brain delivery of drugs addressing the CNS component of a CNS, cardiovascular or metabolic disorder 2) Delivery (oral, injection or otherwise) of a cardiovascular &/or metabolic &/or other agent to the central compartment (i.e., blood and well-perfused org
Absstract of: WO2025076406A1
The synthesis and characterization of a series of derivatives and analogs based on the 9-aminoacridine scaffold shared by antimalarial drugs quinacrine and pyronaridine are described. Also described is the structure-activity relationship of these compounds against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease of 2019 (COVID-19). Several compounds displayed potent in vitro activity, with 50% inhibitory concentrations below 1 micromolar.
Absstract of: WO2025059202A1
Disclosed are methods for detecting if a biological sample (e.g., serum, blood, plasma) contains antibodies against SARS-CoV-2 S glycoproteins comprising: (i) providing a surface coated with a SARS-CoV-2 S glycoprotein; (ii) exposing the surface to the biological sample; (iii) exposing the surface to a secondary antibody; and (iv) detecting the secondary antibody that is bound to the surface; wherein the biological sample contains antibodies that bind to the SARS-CoV-2 S glycoprotein if secondary antibody is detected.
Absstract of: US20260201021A1
0000 Disclosed is a Fv-antibody having a specific binding ability to a cleavage site of a SARS-COV-2 spike protein by TMPRSS2. The Fv-antibody includes a peptide sequence of DPPPPAVAADV or CRDLLGVVRDF.
Absstract of: CN122428060A
The invention relates to the technical field of biological detection, in particular to a nucleic acid detection system based on isothermal-PfAgo-RDB, a kit and a detection method, a primer group comprises F3, B3, FIP, BIP, LF and LB; the nucleic acid detection system comprises a nucleic acid isothermal amplification module, a PfAgo cutting module and an RDB visualization module; the target comprises an SARS-COV-2 O gene and/or an SARS-COV-2 N gene and/or MP (Methyl Pyrrolidone) and/or PIVs (Phosphatidylcholine); the PfAgo cutting module comprises gDNA (deoxyribonucleic acid), PfAgo and a probe; the probe comprises a fluorescent probe and an identification probe; a nucleic acid detection method based on isothermal-PfAgo-RDB comprises the following steps: (1) isothermal amplification: designing primers for target nucleic acid SARS-COV-2 O gene and/or SARS-COV-2 N gene and/or MP and/or PIVs, and carrying out isothermal amplification; (2) PfAgo cutting: guiding PfAgo to carry out specific cutting on a target in the sample through the 5 '-phosphorylated gDNA, so as to obtain a PfAgo treating fluid; and (3) carrying out RDB hybridization and color development. The kit has the advantages of high sensitivity, strong specificity, no cross reaction, high flux, low cost, suitability for mixed infection screening and the like.
Nº publicación: CN122427960A 21/07/2026
Applicant:
UNIV NANJING CHINESE MEDICINE
\u5357\u4EAC\u4E2D\u533B\u836F\u5927\u5B66
Absstract of: CN122427960A
The invention discloses a construction method of a novel coronavirus-like particle induced cell membrane fusion model, and belongs to the technical field of biology, and the method comprises the following steps: constructing virus-like particles containing SARS-CoV-2 spike protein genes and RNA packaging sequence PS9, taking HEK-293T cells as packaging cells, co-expressing structural proteins M, E, N and S, and realizing VLPs assembly without replication ability. And then, infecting immortalized II-type alveolar epithelial cells by using the VLPs, and inducing S protein expression and mediating cell-cell membrane fusion under the condition of not needing a BSL-3 laboratory. The formation of fused giant cells can be visually observed through ZO-1 protein immunofluorescence staining, and the model is stable, high in biological safety and repeatable in vitro. The method overcomes the problems of safety risk of live virus infection and insufficient authenticity of a transient transfection model, can be used for research of an SARS-CoV-2 virus membrane fusion mechanism, and has a good application prospect.
BOPI
Electronic site
